Ahlheim; Markus

Patent Applications and Registrations

Patent applications and USPTO patent grants for Ahlheim; Markus.The latest application filed is for "sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers".

Company Profile

2.11.32

Ahlheim; Markus - Staufen DE
Ahlheim; Markus - Basel CH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Sustained Release Formulation Comprising Octreotide And Two Or More Polylactide-co-glycolide Polymers App 20220296675 - Petersen; Holger ; et al.	2022-09-22
Octreotide Depot Formulation with Constantly High Exposure Levels App 20210161806 - Ahlheim; Markus ; et al.	2021-06-03
Sustained Release Formulation Comprising Octreotide And Two Or More Polylactide-co-glycolide Polymers App 20200206306 - Petersen; Holger ; et al.	2020-07-02
Octreotide depot formulation with constantly high exposure levels App 20190209462 - Ahlheim; Markus ; et al.	2019-07-11
Sustained Release Formulation Comprising Octreotide and Two or More Polylactide-co-glycolide Polymers App 20180140662 - Petersen; Holger ; et al.	2018-05-24
Octreotide Depot Formulation With Constantly High Exposure Levels App 20180036230 - Ahlheim; Markus ; et al.	2018-02-08
Octreotide Depot Formulation With Constantly High Exposure Levels App 20170143791 - Ahlheim; Markus ; et al.	2017-05-25
Sustanined Release Formulation Comprising Octreotide and Two or More Polyactide-co-glycolide Polymers App 20160120935 - Petersen; Holger ; et al.	2016-05-05
Octreotide depot formulation with constantly high exposure levels App 20160089336 - Ahlheim; Markus ; et al.	2016-03-31
Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers Grant 8,999,390 - Petersen , et al. April 7, 2	2015-04-07
Sustained Release Formulation Comprising Octreotide and Two or More Polyactide-co-glycolide Polymers App 20150037420 - Petersen; Holger ; et al.	2015-02-05
Octreotide Depot Formulation with Constantly High Exposure Levels App 20140363513 - Ahlheim; Markus ; et al.	2014-12-11
Organic compounds Grant 8,815,293 - Ahlheim , et al. August 26, 2	2014-08-26
Injectable depot formulation comprising crystals of iloperidone Grant 8,614,232 - Wieckhusen , et al. December 24, 2	2013-12-24
Ophthalmic Depot Formulations for Periocular or Suconjunctival Administration App 20130122064 - Ahlheim; Markus ; et al.	2013-05-16
Injectable Depot Formulation Comprising Crystals Of Iloperidone App 20130012542 - Wieckhusen; Dierk ; et al.	2013-01-10
Injectable depot formulation comprising crystals of iloperidone Grant 8,293,765 - Wieckhusen , et al. October 23, 2	2012-10-23
Sustained Release Formulation Comprising Octreotide And Three Linear Polylactide-co-glycolide Polymers App 20120226224 - Petersen; Holger ; et al.	2012-09-06
Microparticles Comprising Somatostatin Analogues App 20120214749 - Ahlheim; Markus ; et al.	2012-08-23
Injectable depot formulation comprising crystals of iloperidone Grant 8,227,488 - Wieckhusen , et al. July 24, 2	2012-07-24
Injectable Depot Formulation Comprising Crystals Of Iloperidone App 20120156264 - Wieckhusen; Dierk ; et al.	2012-06-21
Microparticles comprising somatostatin analogues Grant 8,188,037 - Ahlheim , et al. May 29, 2	2012-05-29
Octreotide depot formulation with constantly high exposure levels App 20110262545 - Ahlheim; Markus ; et al.	2011-10-27
Injectable Depot Formulation Comprising Crystals Of Iloperidone App 20110212141 - Wieckhusen; Dierk ; et al.	2011-09-01
Sustained Release Formulation Comprising Octreotide And Three Linear Polylactide-co-glycolide Polymers App 20110003002 - Petersen; Holger ; et al.	2011-01-06
Microparticles Comprising Somatostatin Analogues App 20100272809 - Ahlheim; Markus ; et al.	2010-10-28
Octreotide Depot Formulation With Constantly High Exposure Levels App 20100266704 - Ahlheim; Markus ; et al.	2010-10-21
Organic compounds Grant 7,767,230 - Ahlheim , et al. August 3, 2	2010-08-03
Microparticles comprising somatostatin analogues Grant 7,759,308 - Ahlheim , et al. July 20, 2	2010-07-20
Octreotide Depot Formulation With Constantly High Exposure Levels App 20100151033 - Ahlheim; Markus ; et al.	2010-06-17
Injectable Depot Formulation Comprising Crystals Of Iloperidone App 20090099232 - Wieckhusen; Dierk ; et al.	2009-04-16
Sustained Release Formulation Comprising Octreotide and Two or More Polylactide-Co-Glycolide Polymers App 20090004283 - Petersen; Holger ; et al.	2009-01-01
Microparticles comprising somatostatin analogues App 20070212418 - Ahlheim; Markus	2007-09-13
Parenteral formulation of mycophenolic acid, a salt or prodrug thereof App 20060189683 - Ahlheim; Markus	2006-08-24
Injectable depot formulation comprising crystals of iloperidone App 20050250813 - Wieckhusen, Dierk ; et al.	2005-11-10
Organic compounds App 20030091645 - Ahlheim, Markus ; et al.	2003-05-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.